Abstract: The invention relates to an implantable valve (1) for a drainage system for discharging cerebrospinal fluid, comprising: a valve housing (10) extending along a valve axis (A), an inlet (2) and an outlet (3) as well as a valve housing (10) surrounding an interior space (4), a valve body assembly (600) arranged in the interior (4) and movably arranged in the interior space (4), a first valve seat (5), wherein the valve body assembly (600) is configured to abut the first valve seat (5) to close a flow connection between the inlet (2) and the interior space (4) of the valve housing (10), a second valve seat (7) which faces the first valve seat (5), wherein the valve body assembly (600) is configured to abut the second valve seat (7) to close a flow connection between the outlet (3) and the interior space (4) of the valve housing (10), and a spring device (800) arranged in the interior space (4) which exerts a spring force on the valve body assembly (600) in the direction of the first valve seat (5).

Abstract: Multi-component systems and methods for determining the proximity of surgical tools to key anatomical features are provided. The inventive systems and methods can be applied in any surgical procedure requiring precision to avoid damage to key anatomical features such as nerves, with a particular example being the robotic cochlear implantation minimally invasive approach to cochlear implantation. Use of purpose built surgical robots, electromyography and tissue impedance, stereotactic tracking and drilling force/bone density measurements are all key components, with inputs from these various modalities being dynamically weighted. In the example of robotic cochlear implantation, the inventive concepts are used to provide key surgical guidance so as to avoid damage to the facial nerve and the chorda tympani, among other anatomical features.

Abstract: Provided herein is an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

Abstract: An aspect of the invention provides a method and a product for determining a modification of the therapy management by using a processor unit which retrieves few data related to the blood glucose measurement performed over a predetermined time period; retrieve the medication delivery parameter executed by the delivery device over said predetermined time period; retrieve from the memory data associated to the CIR of the patient; and determine a modification to the therapy based on at least a part of the retrieved data.

Abstract: Provided herein is an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

Abstract: A method for producing non-human conditionally immortalized mast cell progenitors comprises: introducing a nucleic acid molecule comprising an inducible homeobox gene into myeloid progenitor cells, wherein said myeloid progenitor cells are derived from a non-human animal and are engineered to express a heterologous high-affinity IgE receptor alpha subunit (Fc?RI?); and selecting for cells which contain the nucleic acid molecule. The non-human conditionally immortalized mast cell progenitors may be cultured to obtain differentiated mast cells. The mast cells find utility in assays for the determination of IgE mediated allergies.

Abstract: Oligomers can be prepared from bicyclic nucleoside. The nucleosides can be a compound of formula (I) in which each of T1 and T2 is independently OR1 or OR2; R1 is H or a hydroxyl protecting group, R2 is a phosphorus moiety; and Bx is a nucleobase. The compounds, bicyclic nucleosides and the oligomers are useful for the prevention, treatment or diagnosis of muscular dystrophy.

Abstract: Provided herein is an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

Abstract: The invention is related to an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.

Abstract: A drill bit (1) for creating a tubular hole in a bone (9), comprises: a longitudinal body (2) extending along an axis (21) and having a proximal end and a distal end (22); a main cutting edge (3) formed at the distal end (22) of the body (2); a main cutting face (4) extending from the main cutting edge (3) and defining a rake angle (?); and a spiral flute (5) formed around the body (2) and extending from the main cutting face (4) along the axis (21) of the body (2). The main cutting edge (3) is the only single main cutting edge (3) of the drill bit (1). The spiral flute (5) is the only single spiral flute (5) of the drill bit. The rake angle (?) is at least 25°. The drill bit (1) according to the invention drill bit allows for minimizing heat production when drilling a hole into the bone.

Abstract: The invention relates to a compound comprising the following general formula (1): and said compound for use as a medicament, in particular for use in the treatment psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (formula 1) wherein each of R1, R2 and R3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.

Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.

Abstract: The invention relates to a modular and stackable system (1) for arranging an optical fibre of an optical system in a controlled and secure manner, comprising at least the following components: a modular frame (30) comprising a plurality of upright posts (31), wherein the posts (31) are arranged such on the frame (30) that a next-neighbour distance of the posts (31) is identical, wherein each post (31) comprises a recess (31a) on the upper end; at least one module (20) for receiving an optical fibre, wherein the module (20) comprises at least four corners (21); wherein the posts (31) are arranged such that four modules (20) can be arranged with their corners (21) non-overlapping on a single post (31); wherein each module's corner (21) can be fixed with a fixing means on the post (31), wherein the fixing means is designed to engage in the recess (31a) on the upper end of the post (31) and wherein the corners (21) of each module (20) and the fixing means are designed such that the fixing means can simultaneously

Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.

Abstract: The invention relates to a compound comprising the following general formula (1): and said compound for use as a medicament, in particular for use in the treatment psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (formula 1) wherein each of R1, R2 and R3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.

Abstract: The invention relates to a compound wherein R1 is selected from —I, —Br, —Cl, —F, C1-C6-alkyl, —O(CH2)mCH3, —(CH2)mOCH3, C1-C6-haloalkyl, a cycloalkyl, a heterocycle, a aryl or heteroaryl, wherein R2 is selected from H, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, —CH2—(C3-C6-cycloalkyl), or —(CH2)rOCH3, wherein R3 is —NH2, —NH—R4, —NHC(?O)—R4, —NHC(?O)NH—R4, —NHC(?S)—R4 or —NHC(?S)NH—R4, wherein R4 is selected from a cycloalkyl, a heterocycle, a aryl or a heteroaryl, or -L-R5, wherein L is selected from C1-C5-alkyl, a cycloalkyl, a heterocycle, a aryl, or a heteroaryl, and R5 is selected from —OH, —CH2OH, —NH2, —COOH, —CONH2, —CONH—R6 or carboxylic acid isosteres, wherein R6 is selected from C1-C4-alkyl, with n, m and r being 0, 1, 2, 3, 4 or 5 and their use.

Abstract: Provided are tricyclo-DNA (tc-DNA) AON and methods employing tc-DNA AON for modifying splicing events that occur during pre-mRNA processing. Tricyclo-DNA (tc-DNA) AON are described that may be used to facilitate exon skipping or to mask intronic silencer sequences and/or terminal stein-loop sequences during pre-mRNA processing and to target RNase-mediated destruction of processed mRNA.

Abstract: A surgical instrument for treating atrioventricular valve prolapse of the drained human heart, includes a handle for being held by a surgeon, a shaft extending distally from the handle, the shaft having a lumen open to a shaft distal end, a cannulated needle arranged in the shaft; with a distal end of the needle protruding from the shaft distal end at least in one possible needle position. The needle accommodates a first, distal implant equipped for being anchored in a papillary muscle, and a second, proximal implant shaped to hold on to a leaflet of an atrioventricular valve, the first and second implants each including a chord connector portion for connecting the respective implant to an artificial chord. The apparatus further includes a trigger arrangement for releasing the first, distal implant upon a first release actuation and for releasing the second, proximal implant upon a second release actuation.

Abstract: The invention relates to a compound comprising the following general formula (1): and said compound for use as a medicament, in particular for use in the treatment psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (formula 1) wherein each of R1, R2 and R3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.